First Midwest Bank Trust Division Purchases New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

First Midwest Bank Trust Division purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 472,604 shares of the biotechnology company’s stock, valued at approximately $1,791,000. First Midwest Bank Trust Division owned about 0.43% of BioCryst Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in BCRX. Paloma Partners Management Co purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $84,000. Amalgamated Bank acquired a new position in BioCryst Pharmaceuticals in the 4th quarter worth $122,000. Summit Securities Group LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter worth $132,000. Legal & General Group Plc lifted its holdings in BioCryst Pharmaceuticals by 14.5% in the 4th quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock worth $156,000 after buying an additional 2,453 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter worth $169,000. 92.35% of the stock is owned by institutional investors.

A number of equities analysts have commented on the stock. Barclays set a €16.80 ($19.53) price objective on shares of Deutsche Telekom and gave the stock a “neutral” rating in a report on Tuesday, April 2nd. Piper Jaffray Companies set a $15.00 price objective on shares of BioCryst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, April 22nd. Jefferies Financial Group cut their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 22nd. BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a report on Wednesday, July 24th. Finally, JMP Securities cut their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, May 23rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $9.56.

Shares of BCRX traded down $0.01 during midday trading on Tuesday, hitting $3.13. The company had a trading volume of 20,671 shares, compared to its average volume of 1,089,996. The firm has a 50 day moving average price of $3.55. The stock has a market cap of $346.37 million, a PE ratio of -3.19 and a beta of 2.05. BioCryst Pharmaceuticals, Inc. has a 52 week low of $2.80 and a 52 week high of $9.95. The company has a current ratio of 1.77, a quick ratio of 1.76 and a debt-to-equity ratio of 2.38.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). The business had revenue of $5.89 million during the quarter, compared to the consensus estimate of $2.92 million. BioCryst Pharmaceuticals had a negative net margin of 472.12% and a negative return on equity of 223.34%. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.21 EPS for the current fiscal year.

In other news, CFO Thomas R. Staab II sold 7,750 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $7.30, for a total value of $56,575.00. Following the transaction, the chief financial officer now owns 140,426 shares of the company’s stock, valued at approximately $1,025,109.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas R. Staab II sold 19,500 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $7.70, for a total transaction of $150,150.00. Following the completion of the transaction, the insider now directly owns 142,426 shares in the company, valued at approximately $1,096,680.20. The disclosure for this sale can be found here. Insiders sold a total of 67,500 shares of company stock valued at $517,223 in the last 90 days. Corporate insiders own 5.20% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: What are the components of an earnings report?

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.